Literature DB >> 33601053

USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.

Min Li1, Yanqin Xu1, Jie Liang2, Hao Lin2, Xinyue Qi2, Fanlin Li2, Ping Han2, Yanfeng Gao3, Xuanming Yang4.   

Abstract

Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated 9 (Cas9)-mediated loss-of-function screens are powerful tools for identifying genes responsible for diverse phenotypes. Here, we perturbed genes in melanoma cells to screen for genes involved in tumor escape from T cell-mediated killing. Multiple interferon gamma (IFNγ) signaling-related genes were enriched in melanoma cells resistant to T cell killing. In addition, deletion of the deubiquitinating protease ubiquitin specific peptidase 22 (USP22) in mouse melanoma (B16-OVA) cells decreased the efficacy of T cell-mediated killing, both in vitro and in vivo, while overexpression enhanced tumor-cell sensitivity to T (OT-I) cell-mediated killing. USP22 deficiency in both mouse and human melanoma cells showed impaired sensitivity to interferon pathway and USP22 was positively correlated with key molecules of interferon pathway in clinical melanoma samples. Mechanistically, USP22 may directly interact with signal transducer and activator of transcription 1 (STAT1), deubiquitinate it, and improve its stability in both human and mouse melanoma cells. Our findings identified a previously unknown function of USP22 and linked the loss of genes in tumor cells that are essential for escaping the effector function of CD8+ T cells during immunotherapy.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  STAT1; USP22; deubiquitination; immunotherapy

Mesh:

Substances:

Year:  2021        PMID: 33601053      PMCID: PMC8178440          DOI: 10.1016/j.ymthe.2021.02.018

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  73 in total

1.  Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

Authors:  Maria Kleppe; Idoya Lahortiga; Tiama El Chaar; Kim De Keersmaecker; Nicole Mentens; Carlos Graux; Katrien Van Roosbroeck; Adolfo A Ferrando; Anton W Langerak; Jules P P Meijerink; François Sigaux; Torsten Haferlach; Iwona Wlodarska; Peter Vandenberghe; Jean Soulier; Jan Cools
Journal:  Nat Genet       Date:  2010-05-16       Impact factor: 38.330

2.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Authors:  Rikke Lyngaa; Natasja Wulff Pedersen; David Schrama; Charlotte Albæk Thrue; Dafina Ibrani; Ozcan Met; Per Thor Straten; Paul Nghiem; Jürgen C Becker; Sine Reker Hadrup
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

5.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

Authors:  Xuanming Yang; Xunmin Zhang; May Lynne Fu; Ralph R Weichselbaum; Thomas F Gajewski; Yajun Guo; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

6.  Alternative activation of STAT1 and STAT3 in response to interferon-gamma.

Authors:  Yulan Qing; George R Stark
Journal:  J Biol Chem       Date:  2004-07-27       Impact factor: 5.157

Review 7.  Histone H2B monoubiquitination: roles to play in human malignancy.

Authors:  Alexander J Cole; Roderick Clifton-Bligh; Deborah J Marsh
Journal:  Endocr Relat Cancer       Date:  2014-06-02       Impact factor: 5.678

Review 8.  Immune modulation in cancer with antibodies.

Authors:  David B Page; Michael A Postow; Margaret K Callahan; James P Allison; Jedd D Wolchok
Journal:  Annu Rev Med       Date:  2013-10-30       Impact factor: 13.739

9.  USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses.

Authors:  Qiang Zou; Jin Jin; Hongbo Hu; Haiyan S Li; Simona Romano; Yichuan Xiao; Mako Nakaya; Xiaofei Zhou; Xuhong Cheng; Peirong Yang; Guillermina Lozano; Chengming Zhu; Stephanie S Watowich; Stephen E Ullrich; Shao-Cong Sun
Journal:  Nat Immunol       Date:  2014-04-28       Impact factor: 25.606

10.  Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.

Authors:  Aidong Zhou; Kangyu Lin; Sicong Zhang; Yaohui Chen; Nu Zhang; Jianfei Xue; Zhongyong Wang; Kenneth D Aldape; Keping Xie; James R Woodgett; Suyun Huang
Journal:  Nat Cell Biol       Date:  2016-08-08       Impact factor: 28.824

View more
  3 in total

Review 1.  miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma.

Authors:  Mai-Huong Thi Nguyen; Yueh-Hsia Luo; An-Lun Li; Jen-Chieh Tsai; Kun-Lin Wu; Pei-Jung Chung; Nianhan Ma
Journal:  Biomolecules       Date:  2021-11-08

Review 2.  The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma.

Authors:  Yi Shi; Ji-Bin Liu; Jing Deng; Da-Zhi Zou; Jian-Jun Wu; Ya-Hong Cao; Jie Yin; Yu-Shui Ma; Fu Da; Wen Li
Journal:  Hereditas       Date:  2021-11-10       Impact factor: 3.271

Review 3.  Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis.

Authors:  Mickael Ohanna; Pierric Biber; Marcel Deckert
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.